Drugs / UniCAR02-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04230265 | Jan 2020 → Apr 2025 | acute myeloid leukemia | AvenCell Europe GmbH | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04633148 Background | Nov 2020 → Mar 2024 | prostate cancer | AvenCell Europe GmbH | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UniCAR02-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04633148 ↗ |
| Action | Deplete | “UniCAR-T efficiently eradicated CD123+ leukemia in vitro and in vivo.” PMID 32462078 ↗ Apr 2020 |
| Modality | Cell therapy | “genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T)” NCT04230265 ↗ |
| Route | Intravenous | “Intravenous infusion of single dose” NCT04230265 ↗ |